KANSAS CITY, Missouri — Biological detection and diagnostics company Evogen Inc. has raised a little over $1 million, according to a filing with the U.S. Securities and Exchange Commission.
Evogen hopes to raise $2 million, according to the document. It’s unclear what the company plans to do with the funding. Chief Executive Sean Reineke didn’t immediately return a call.
The company’s air-sampling technology is designed for use in a number of industries, including biodefense, clinical, research and environmental.
The Power of One: Redefining Healthcare with an AI-Driven Unified Platform
In a landscape where complexity has long been the norm, the power of one lies not just in unification, but in intelligence and automation.
Formerly known as Sceptor Industries Inc., the company formed in 2002 as a spin-off from the Kansas City-based Midwest Research Institute shortly after the anthrax scare in the wake of the Sept. 11 terrorist attacks. It changed its name to Evogen in 2008 after acquiring a United Kingdom-based molecular diagnostics company of the same name.
The company scored perhaps its biggest win in 2003 when it signed a two-year, $42 million deal to supply the U.S. Post Office with about 1,700 aerosol-collection, air-monitoring devices, the Kansas City Business Journal reported. That device, called SpinCon, is Evogen’s best-known technology and is used by commercial, government and military customers.
Entrepreneur magazine named Evogen its No. 16 fastest-growing U.S. business in 2005, the Business Journal reported.
In late 2008, Evogen announced that it had raised $3 million in a Series B round of funding from New York-based L Capital Partners. The company raised $1.5 million in 2002, according to an SEC filing.
MedCity News Pivot Podcast: How Emergency Departments Are Using Real-Time Data to Improve Outcomes
How can AI benefit and improve patient outcome in the emergency department? Watch the latest episode to find out.
The company hasn’t issued a press release since January 2009, when it bought licensing rights from a U.K. firm for a molecular-diagnostic technology called HyBeacons.
The company has offices in Kansas City, Maryland and the United Kingdom.